Developing the next generation of oncolytic immunotherapy.

Oncolytic immuno-gene therapy is an emerging class of cancer therapeutics which exploit the ability of viruses to selectively replicate in and kill tumors, while at the same time inducing a potent, patient-specific, anti-tumor immune response. Oncolytic viruses have the unique ability to generate an autologous immune response to the patient’s particular complement of tumor antigens, including neoantigens, with a truly off-the-shelf approach. While clear single agent clinical activity has been achieved with oncolytic immuno-gene therapy, it is anticipated that enhanced efficacy may be seen in combination with other cancer therapies, including immune checkpoint blockade.